RxDoctor Payments DataLook up a doctor →

Skyler Martin

Family · Foley, ALNPI 1093195091

Payments from drug & device makers

$16,888in general payments, 2019–2025

Across 581 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Myriad Genetic Laboratories, Inc.$6K
  • Novartis$1K
  • AstraZeneca$989
  • Merck$865
  • Johnson & Johnson$576
  • Bristol Myers Squibb$572
  • plus $7K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Myriad Genetic Laboratories, Inc.13$5,577
Novartis63$1,175
AstraZeneca(2 entities)40$989
Merck40$865
Johnson & Johnson33$576
Bristol Myers Squibb29$572
Daiichi Sankyo Inc.28$562
Amgen26$504
Eisai Inc.23$446
Incyte Corporation20$367
Lilly USA, LLC19$356
Pfizer19$320
Regeneron Healthcare Solutions, Inc.11$294
E.r. Squibb & Sons, L.L.C.16$255
Astellas Pharma US Inc15$247
Genentech USA, Inc.12$239
Seagen Inc.12$217
Sanofi10$211
Ipsen Biopharmaceuticals, Inc8$199
AbbVie8$187
Takeda Pharmaceuticals U.S.A., Inc.8$186
Bayer9$173
Deciphera Pharmaceuticals Inc.8$166
GSK7$135
Boehringer Ingelheim5$135
Exelixis Inc.6$110
Blueprint Medicines Corporation5$107
Pharmacyclics LLC, An Abbvie Company6$105
Beigene USA, Inc.7$104
Beone Medicines USA, Inc.5$102
Pharmaessentia USA Corporation4$92
Tersera Therapeutics LLC3$90
Stemline Therapeutics Inc.4$84
Servier Pharmaceuticals LLC4$79
Progenics Pharmaceuticals, Inc.4$77
Puma Biotechnology, Inc.4$75
Karyopharm Therapeutics Inc.4$71
AVEO Pharmaceuticals, Inc.3$61
Array Biopharma Inc3$61
Mirati Therapeutics, Inc.3$58
EMD Serono, Inc.4$56
Sobi, Inc2$56
Taiho Oncology, Inc.3$55
ADC Therapeutics America, Inc.3$53
Janssen Scientific Affairs, LLC1$42
Coherus Oncology, Inc.1$41
Heron Therapeutics, Inc.1$41
Genmab U.S., Inc.2$41
Adaptive Biotechnologies Corporation2$39
Acrotech Biopharma Inc.2$37
Gilead2$31
Apellis Pharmaceuticals, Inc.2$30
Morphosys, US Inc.2$28
Cumberland Pharmaceuticals, Inc.1$19
Rigel Pharmaceuticals, Inc.1$17
Azurity Pharmaceuticals, Inc.1$16
Sumitomo Pharma America, Inc.1$16
Acceleron Pharma, Inc.1$15
Pharmacosmos Therapeutics Inc.1$15
Clovis Oncology, Inc.1$12

How this compares

$16,888 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama →

Medicare billing

Part B allowed, 2024
$274,449
Medicare patients
406
Services billed
16,585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family in Foley

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →